Skip to main content
. 2021 Oct 19;64(12):1512–1520. doi: 10.1111/myc.13376

TABLE 3.

Results of antifungal susceptibility testing of Candida isolates from the two study periods (period 1:2004‐2006, and period 2:2014‐2017)

Candida species Period

Antifungal drug

MIC50/MIC90 (µg/ml)

(range)

% resistant (R) isolatesa

Fluconazole Voriconazole Posaconazole Amphotericin B Caspofungin Anidulafungin Micafungin
Candida albicans

Period 1

0.25 / 0.50

(0.06‐1)

R : 0%

0.01 / 0.02

(0.01‐0.06)

R : 0%

0.5 / 0.5

(0.13‐1)

ND

0.032 / 0.13

(<0.03‐0.25)

R : 0%

Period 2

0.25 / 0.50

(<0.06‐2)

R : 0%

/ 0.03

(<0.008‐0.12)

R : 0%

0.015 / 0.042

(0.015‐0.50)

ND

0.5 / 1

(0.05‐1)

ND

0.03 / 0.06

(<0.03‐1)

R :2%

0.03 / 0.06

(<0.03‐0.25)

R : 0%

0.01 / 0.03

(<0.01 ‐ 0.5)

R : 0%

Candida glabrata

Period 1

16 / 64

(4‐128)

R : 12%

0.25 / 0.5

(0.06‐2)

ND

0.5 / 1

(0.13‐1)

ND

0.06 / 0.13

(0.02‐0.25)

R :0%

Period 2

8 / 16

(1‐32)

R :0%

0.25 / 0.5

(0.06‐4)

ND

0.5 / 2

(0.05‐2)

ND

1 / 1

(0.06‐1)

ND

0.06 / 0.13

(0.03‐0.25)

R : 0%

0.03 / 0.06

(<0.03‐1)

R : 6%

0.015 / 0.015

(<0.01‐0.12)

R : 0%

Candida tropicalis

Period 1

1 / 2

(0.5‐4)

R : 0%

0.03 / 0.25

(0.01‐0.25)

R : 0%

0.25 / 0.5

(0.13‐0.5)

ND

0.03 / 0.5

(0.03‐0.5)

R : 0%

Period 2

2 / 2

(0.25‐2)

R : 0%

0.12 / 0.25

(0.01‐0.25)

R : 0%

0.12 / 0.5

(0.02‐0.5)

ND

0.5 / 1

(0.5‐1)

ND

0.03 / 0.12

(0.02‐0.12)

R : 0%

0.03 / 0.12

(0.02 ‐ 0.12)

R : 0%

0.02 / 0.06

(0.02‐0.12)

R : 0%

Candida parapsilosis

Period 1

2 / 2

(2‐2)

R : 0%

0.03 / 0.03

(0.03)

R : 0%

0.25 / 0.5

(0.25 / 0.5)

ND

0.25 / 0.5

(0.25‐0.5)

R : 0%

Period 2

0.5 / 0.5

(0.5)

R : 0%

0.008 / 0.01

(0.008‐0.02)

R : 0%

0.015 / 0.026

(<0.015 ‐ 0.026)

ND

0.5 / 0.5

(0.25‐0.5)

ND

0.5 / 0.5

(0.25‐0.5)

R : 0%

1 / 2

(1‐2)

R : 0%

1 / 2

(1 −2)

R : 0%

Candida krusei

Period 1

64

ND

0.25

R : 0%

1

ND

1

R :100%

Period 2

32

ND

0.5 /0.5

(0.25‐0.5)

R : 0%

0.25 / 0.25

(0.25)

ND

0.5 / 1

(0.5 ‐ 1)

ND

0.25 / 0.5

(0.25 −0.5)

R : 0%

0.06 / 0.06

(0.03‐0.06)

R : 0%

0.12 / 0.12

(0.12)

R : 0%

MIC50/MIC90: Minimum inhibitory concentration encompassing 50% and 90% of isolates, respectively. R: resistant isolates according to the Clinical and Laboratory Standards Institute (CLSI) criteria. 15 ND: no defined criteria.